Levetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Inducing Critical Molecular Changes in the Striatum

Figure 4

Levetiracetam-induced changes in the phosphorylation of DARPP-32 in the dorsolateral portion of the striatum. (a) Images display immunoblots from striatal tissue (lesioned and unlesioned side) from one animal in each levetiracetam treatment group. Immunoblots correspond to p-DARPP-32 and β-actin as internal control. The graph compares p-DARPP-32 expression across treatment groups. Levetiracetam 60 mg/kg significantly reduced the striatal p-DARPP-32 expression. versus same side of the control group. (b) Images display immunoblots from striatal tissue (IL: ipsilateral side; CL: contralateral side) from one animal in each levetiracetam treatment group. Immunoblots correspond to total DARPP-32 and β-actin as internal control. The graph compares total DARPP-32 expression across treatment groups. Levetiracetam had nonsignificant effects on the striatal total DARPP-32 expression ( per group; LEV: levetiracetam).

(a)

(b)